Peptides · Peptide comparison
Mazdutide vs Survodutide
Dual GLP-1/glucagon receptor agonist delivering up to 20% weight loss with superior glycemic control in clinical trials.
Dual GLP-1/glucagon receptor agonist for obesity and metabolic liver disease
- Weight Management
- Weight Management
At a glance
Quick comparison
Dose rangeMazdutide4–4 mgSurvodutide3.6–3.6 mg
FrequencyMazdutideOnce dailySurvodutideOnce daily
AdministrationMazdutideSubcutaneous injectionSurvodutidesubcutaneous injection
Cycle lengthMazdutideOngoing/indefiniteSurvodutideOngoing/indefinite
Onset speedMazdutideModerate (1-2 weeks)SurvodutideModerate (1-2 weeks)
Evidence levelMazdutideStrong human trials (Phase 3 or FDA approved)SurvodutideStrong human trials (Phase 3 or FDA approved)
Efficacy
Benefit ratings
Weight Loss
Blood Sugar Control
Metabolic Health
Weight Management
Technical data
Compound specifications
Mazdutide
- Molecular formula
- C210H322N46O67
- Molecular weight
- 4563.1 Da
- Half-life
- Approximately 8 days
- Bioavailability
- Subcutaneous bioavailability characteristic of acylated peptide analogs
- CAS number
- 2259884-03-0
Survodutide
- Molecular formula
- C192H289N47O61
- Molecular weight
- 4,231.6 Da
- Half-life
- ~7 days (enabling once-weekly dosing)
- Bioavailability
- Optimized for subcutaneous administration with C18 acylation
- CAS number
- 2805997-46-8
Protocols
Dosing compared
Mazdutide
Subcutaneous
- Initial titration weeks1.5 mgOnce weekly · Initial titration weeksGLORY-1 Phase 3 starting dose; mazdutide was initiated at 1.5 mg once weekly and titrated stepwise toward the target maintenance dose to limit GI effects [6].
- Weeks 32-484 mgOnce weekly · Maintenance (32-48 weeks in trial)GLORY-1 Phase 3 maintenance dose; produced about 11-12% mean body-weight reduction. Approved in China at this strength for weight management [6].
- Weeks 32-486 mgOnce weekly · Maintenance (32-48 weeks in trial)GLORY-1 Phase 3 higher maintenance dose; produced about 13-15% mean body-weight reduction. Approved in China at this strength alongside the 4 mg dose [6].
Survodutide
Subcutaneous
- Initiation, part of a 20-week up-titration0.6 mgOnce weekly · Initiation, part of a 20-week up-titrationPhase 2 starting dose; gradual escalation reduces GI side effects [1].
- 26-week maintenance after escalation3.6 mgOnce weekly · 26-week maintenance after escalationMaintenance dose in the phase 2 dose-finding trial; ~12.5% mean weight loss [1].
- 26-week maintenance after escalation4.8 mgOnce weekly · 26-week maintenance after escalationHighest dose studied; up to ~14.9% mean weight loss over 46 weeks [1].
Applications
Best suited for
Mazdutide
- Individuals seeking substantial weight loss exceeding 15% body weight
- Mazdutide is particularly well-suited for individuals focused on individuals seeking substantial weight loss exceeding 15% body weight. [6][7] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Adults with type 2 diabetes requiring superior glycemic management
- Mazdutide is particularly well-suited for individuals focused on adults with type 2 diabetes requiring superior glycemic management. [1][15] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Patients with obesity-related metabolic comorbidities
- Mazdutide is particularly well-suited for individuals focused on patients with obesity-related metabolic comorbidities. [6][18] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Those seeking dual-mechanism metabolic therapy
- Mazdutide is particularly well-suited for individuals focused on those seeking dual-mechanism metabolic therapy. [4][5] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Survodutide
- Significant body weight reduction in obesity
- Survodutide is particularly well-suited for individuals focused on significant body weight reduction in obesity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- MASH/NASH resolution and liver fibrosis improvement
- Survodutide is particularly well-suited for individuals focused on mash/nash resolution and liver fibrosis improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Type 2 diabetes management with concurrent weight loss goals
- Survodutide is particularly well-suited for individuals focused on type 2 diabetes management with concurrent weight loss goals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Enhanced metabolic outcomes through dual receptor engagement
- Survodutide is particularly well-suited for individuals focused on enhanced metabolic outcomes through dual receptor engagement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety profile
Side effects
Mazdutide
Common
- Nausea
- Diarrhea
- Decreased Appetite
Uncommon
- Vomiting
- Injection Site Reactions
Serious
- Acute Pancreatitis
- Acute Cholecystitis and Biliary Disease
- Severe Nausea and Gastrointestinal Intolerance
Survodutide
Common
- Nausea
- Vomiting
- Diarrhea
- Decreased Appetite
Uncommon
- Constipation and Abdominal Pain
Serious
- Acute Pancreatitis
Research status
Safety & evidence
Mazdutide
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- Research compound
- Safety overview
- Mazdutide (Innovent/Lilly GLP-1 and glucagon dual agonist) is approved in China for weight management and type 2 diabetes. [4] Its safety profile is dominated by gastrointestinal side effects, mostly mild to moderate. [7][11] Nausea/vomiting occur in 40-50% of subjects at higher doses; [7][12] weight loss averaging 12-18% observed. [6][7] Pancreatitis risk monitoring required; [9][10] calcitonin was monitored, with no values of 20 ng/L or higher in phase 2. [9] Heart rate increases 5-9 bpm; [9] no serious cardiac safety signals. Developmental program focuses on tolerability optimization.
Contraindications
- Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- Known hypersensitivity to mazdutide or any formulation excipients
- History of severe pancreatitis
- Severe renal impairment (eGFR <15 mL/min) without clinical data
Survodutide
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- Research compound
- Safety overview
- Survodutide data comes from Phase 2 obesity and MASH trials with dose-dependent gastrointestinal side effects (gastrointestinal events in 75% on survodutide vs 42% on placebo in the obesity trial [1]; nausea 66%, diarrhea 49% and vomiting 41% in the MASH trial [6]) that mirror GLP-1 receptor agonist class effects but occur with greater frequency due to additional glucagon receptor activation increasing energy expenditure. Pancreatitis risk exists as with all GLP-1 agonists—baseline lipase evaluation and patient education on warning signs (persistent upper abdominal pain) are essential. Medullary thyroid carcinoma risk, though theoretical based on GLP-1 class, contraindicates use in MEN 2 or personal thyroid cancer history.
Contraindications
- Personal or family history of medullary thyroid carcinoma (GLP-1 class warning)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to survodutide or excipients
- History of pancreatitis (caution advised with GLP-1 receptor agonists)
Decision guide
Which is right for you?
Mazdutide
Choose Mazdutide if…
- Individuals seeking substantial weight loss exceeding 15% body weight
- Adults with type 2 diabetes requiring superior glycemic management
- Patients with obesity-related metabolic comorbidities
- Those seeking dual-mechanism metabolic therapy
Survodutide
Choose Survodutide if…
- Significant body weight reduction in obesity
- MASH/NASH resolution and liver fibrosis improvement
- Type 2 diabetes management with concurrent weight loss goals
- Enhanced metabolic outcomes through dual receptor engagement